Heartsciences announces allowance of u.s patent for ai-ecg assessment of left ventricular and right ventricular heart dysfunction

Southlake, texas, july 11, 2024 (globe newswire) -- heart test laboratories, inc. d/b/a heartsciences (nasdaq: hscs; hscsw) (“heartsciences” or the “company”), an artificial intelligence (ai)-powered medical technology company focused on transforming ecgs/ekgs to save lives through earlier detection of heart disease, today announced that intellectual property (ip) exclusively licensed to heartsciences has received a notice of allowance from the united states patent and trademark office (uspto) for the detection of left ventricular (lv) and/or right ventricular (rv) dysfunction using deep learning, further strengthening the company's ai-ecg ip portfolio. heart failure (hf) is a growing worldwide public health issue affecting 64 million people annually1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.
HSCS Ratings Summary
HSCS Quant Ranking